|
|
||||||||
,
* Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037;
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; and
Department of Medicine, Harvard Medical School, Boston, MA 02115
Mechanisms contributing to the development of chronic viral infections, including chronic hepatitis B virus (HBV) infections, are not well understood. We have shown recently that production of IFN-
, an important antiviral cytokine, by HBV-specific CTLs is rapidly induced when they enter the liver of HBV transgenic mice, and then rapidly suppressed, despite the continued presence of Ag. Suppression of IFN-
production by the CTLs coincides with the up-regulation of programmed cell death (PD)-1, a cell surface signaling molecule known to inhibit T cell function. To determine whether PD-1 plays a role in the functional suppression of IFN-
secretion by CTLs, we treated HBV transgenic mice with blocking Abs specific for PD ligand (PD-L)1, the most widely expressed PD-1 ligand, and adoptively transferred HBV-specific CTLs. Treatment with anti-PD-L1 Abs resulted in a delay in the suppression of IFN-
-producing CTLs and a concomitant increase in the absolute number of IFN-
-producing CTLs in the liver. These results indicate that PD-1:PD-L1 interactions contribute to the suppression of IFN-
secretion observed following Ag recognition in the liver. Blockade of inhibitory pathways such as PD-1:PD-L1 may reverse viral persistence and chronic infection in cases in which the CTL response is suppressed by this mechanism.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by National Institutes of Health Grants R01 CA40489-21 (to F.V.C.) and P01 AI56299 and a Gates Grand Challenges in Global Health award (to G.J.F.). H.M. was supported by National Institutes of Health Grant T32 AI07244-22 and a Cancer Research Institute postdoctoral fellowship.
2 Address correspondence and reprint requests to Dr. Francis V. Chisari, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, SBR10, La Jolla, CA 92037. E-mail address: fchisari{at}scripps.edu
3 Abbreviations used in this paper: HBV, hepatitis B virus; IHL, intrahepatic lymphocyte; Irr mAb, irrelevant mAb; LCMV, lymphocytic choriomeningitis virus; LNPC, liver nonparenchymal cell; LSEC, liver sinusoidal endothelial cell; PD, programmed cell death; PD-L, PD ligand; sALT, serum alanine aminotransferase.
This article has been cited by other articles:
![]() |
J. O. Jurado, I. B. Alvarez, V. Pasquinelli, G. J. Martinez, M. F. Quiroga, E. Abbate, R. M. Musella, H. E. Chuluyan, and V. E. Garcia Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis J. Immunol., July 1, 2008; 181(1): 116 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Rowe, T. M. Johanns, J. M. Ertelt, and S. S. Way PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes J. Immunol., June 1, 2008; 180(11): 7553 - 7557. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ou, M. Zhang, L. Huang, and D. Moskophidis Control of Virus-Specific CD8+ T-Cell Exhaustion and Immune-Mediated Pathology by E3 Ubiquitin Ligase Cbl-b during Chronic Viral Infection J. Virol., April 1, 2008; 82(7): 3353 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Lukens, M. W. Cruise, M. G. Lassen, and Y. S. Hahn Blockade of PD-1/B7-H1 Interaction Restores Effector CD8+ T Cell Responses in a Hepatitis C Virus Core Murine Model J. Immunol., April 1, 2008; 180(7): 4875 - 4884. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Kemball, C. D. Pack, H. M. Guay, Z.-N. Li, D. A. Steinhauer, E. Szomolanyi-Tsuda, and A. E. Lukacher The Antiviral CD8+ T Cell Response Is Differentially Dependent on CD4+ T Cell Help Over the Course of Persistent Infection J. Immunol., July 15, 2007; 179(2): 1113 - 1121. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |